18 F-DCFPyL-PET/CT in Detecting PSMA Expression in Patients with Metastatic Triple Negative Breast Cancer

This phase II trial tests how well 18F-DCFPyL positron emission tomography (PET)/computed tomography (CT) scan works in detecting a specific molecule called prostate-specific antigen (PSMA) in patients with triple negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research,18F-DCFPyL. Because some cancers take up 18F-DCFPyL it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. 18 F-DCFPyL-PET/CT may be effective in detecting PSMA expression (level) in patients with metastatic TNBC.

Additional locations may be listed on ClinicalTrials.gov for NCT06586047.

Trial PhasePhase II

Trial Typediagnostic

Lead OrganizationUniversity of Iowa/Holden Comprehensive Cancer Center

Principal InvestigatorAhmad Shariftabrizi

• Primary ID202306462
• Secondary IDsNCI-2024-06869
• ClinicalTrials.gov IDNCT06586047